The importance of integrated therapies on cancer: Silibinin, an old and new molecule

Elisa Roca _, Giuseppe Colloca, Fiorella Lombardo, Andrea Bellieni, Alessandra Cucinella, Giorgio Madonia, Licia Martinelli, Maria Elisa Damiani, Ilaria Zampieri and Antonio Santo

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2024; 15:345-353. https://doi.org/10.18632/oncotarget.28587

Metrics: PDF 179 views  |   Full Text 1097 views  |   ?  


Elisa Roca1, Giuseppe Colloca2, Fiorella Lombardo1, Andrea Bellieni2, Alessandra Cucinella1, Giorgio Madonia1, Licia Martinelli1, Maria Elisa Damiani1, Ilaria Zampieri1 and Antonio Santo1

1 Oncologia Toracica - Lung Unit, Ospedale P. Pederzoli - Via Monte Baldo, Peschiera del Garda (VR), Italy

2 Dipartimento di Scienze dell’invecchiamento, Neurologiche, Ortopediche e della testa-collo, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy

Correspondence to:

Elisa Roca, email: [email protected],
ORCID: orcid.org/0000-0001-7625-7708

Keywords: silibinin; anti-inflammatory; inflammation; toxicity; integrated therapy

Received: March 19, 2024     Accepted: May 06, 2024     Published: May 23, 2024

Copyright: © 2024 Roca et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


In the landscape of cancer treatments, the efficacy of coadjuvant molecules remains a focus of attention for clinical research with the aim of reducing toxicity and achieving better outcomes.

Most of the pathogenetic processes causing tumour development, neoplastic progression, ageing, and increased toxicity involve inflammation. Inflammatory mechanisms can progress through a variety of molecular patterns. As is well known, the ageing process is determined by pathological pathways very similar and often parallel to those that cause cancer development. Among these complex mechanisms, inflammation is currently much studied and is often referred to in the geriatric field as ‘inflammaging’.

In this context, treatments active in the management of inflammatory mechanisms could play a role as adjuvants to standard therapies.

Among these emerging molecules, Silibinin has demonstrated its anti-inflammatory properties in different neoplastic types, also in combination with chemotherapeutic agents.

Moreover, this molecule could represent a breakthrough in the management of age-related processes.

Thus, Silibinin could be a valuable adjuvant to reduce drug-related toxicity and increase therapeutic potential.

For this reason, the main aim of this review is to collect and analyse data presented in the literature on the use of Silibinin, to better understand the mechanisms of the functioning of this molecule and its possible therapeutic role.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28587